In cancer, overexpression of HNRNPK promotes tumor progression and correlates with poor patient survival [8], likely by directly affecting the expression and activities of oncogenes and tumor suppressors such as EIF4E [9], c-MYC [10], c-SRC [11] and MDM2 [12]. This evidence concerns the gene HNRNPK and cancer.